Skip to main content
. 2018 Apr 3;9(25):17554–17563. doi: 10.18632/oncotarget.24785

Figure 2.

Figure 2

PD-L1 plasma levels at baseline (A) and after 3 months of first-line treatment (B) in subgroup of patients receiving chemotherapy (red) or no chemotherapy (blue) agents.